Letter Agreement, dated September 3, 2020, with Qorvo Biotechnologies, LLC

EX-10.10 7 exh_1010.htm EXHIBIT 10.10

Exhibit 10.10


   18683 Bearpath Trail

Eden Prairie, MN 55347


Telephone ###-###-####



Robert Cohen

Chief Executive Officer

September 3, 2020


Mr. Hanjoon Ryu

General Manager

Qorvo Biotechnologies, LLC

14205 21st Avenue North (Suite 212)

Plymouth, MN 55447


Dear Hanjoon:


In partial fulfillment of the final Milestone Event set forth in Section 6.1 of the Development and Supply Agreement between Qorvo Biotechnologies, LLC ("Qorvo") and Zomedica Pharmaceuticals Corp. ("Zomedica") dated November 26, 2018 (the "Original Agreement") and amended August 14, 2020, Zomedica hereby identifies the sixth and seventh assays to be developed pursuant to Section 3.4 of the Original Agreement as follows:


Assay #6:  Canine Pancreatic Lipase (cPL) - Pancreatic Biomarker
Species:  Canine
Matrix:  Serum
Assay #7:  Cobalamin (Vitamin B12) - Distal Small Intestine Biomarker
Species:  Canine
Matrix:  Serum


In addition, we have identified the eighth assay to be developed with Assay #6 and Assay #7 above in order to comprise a complete gastrointestinal panel:


Assay #8:  Folate (Vitamin B9) - Proximal Small Intestine Biomarker
Species:  Canine
Matrix:  Serum


If you are in agreement with the above, kindly sign and return this document to me. We then will forward the $2 million milestone payment promptly.


Best regards,


/s/ Robert Cohen


Robert Cohen




Qorvo Biotechnologies, LLC


Signature:  /s/ Hanjoon Ryu  
Name:  Hanjoon Ryu  
Date:  September 4, 2020